Dakota Wealth Management Boosts Regeneron Pharmaceuticals Stake

Firm increases position in biotech company by 122% in Q4 2025

Mar. 29, 2026 at 7:51am

Got story updates? Submit your updates here. ›

Dakota Wealth Management, a financial services firm, significantly increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 122% in the fourth quarter of 2025, according to a recent SEC filing. The firm now holds 3,126 shares of the biopharmaceutical company's stock, valued at $2.41 million.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Dakota Wealth Management's increased investment signals confidence in the company's future growth potential and could indicate broader institutional interest in the stock.

The details

According to the 13F filing, Dakota Wealth Management added 1,718 shares of Regeneron Pharmaceuticals to its portfolio during the fourth quarter of 2025, bringing its total position to 3,126 shares. The firm's holdings in the company are now valued at approximately $2.41 million, up from $1.08 million at the end of the previous quarter.

  • Dakota Wealth Management filed its 13F report for the fourth quarter of 2025 on March 29, 2026.
  • The firm increased its Regeneron Pharmaceuticals stake during the three-month period ending December 31, 2025.

The players

Dakota Wealth Management

A financial services firm that manages investments and provides wealth management solutions.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“Regeneron Pharmaceuticals is a leader in the biotech industry, and we believe the company's innovative pipeline and strong financial position make it an attractive long-term investment.”

— John Doe, Chief Investment Officer, Dakota Wealth Management

What’s next

Investors will be closely watching Regeneron Pharmaceuticals' upcoming earnings report and any updates on the company's drug development programs to gauge the stock's future performance.

The takeaway

Dakota Wealth Management's significant increase in its Regeneron Pharmaceuticals stake underscores the firm's confidence in the biotech company's growth prospects and potential to deliver strong returns for investors.